InnoCan Pharma (FRA:IP40) Current Deferred Taxes Liabilities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IP40 InnoCan Pharma Corp FRA:IP40
62 GF Score
Price €1.51
GF Value €9.51
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Current Deferred Taxes Liabilities?

InnoCan Pharma FRA:IP40 +4.51% 62 Current Deferred Taxes Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.51 (Possible Value Trap). The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

InnoCan Pharma's current deferred tax liabilities for the quarter that ended in Mar. 2026 was €0.00 Mil.

InnoCan Pharma Current Deferred Taxes Liabilities Related Terms

InnoCan Pharma Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Current Deferred Taxes Liabilities Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:IP40
62GF Score
InnoCan Pharma Corp FRA:IP40
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of €0.00 Mil mean?
InnoCan Pharma (FRA:IP40) has a Current Deferred Taxes Liabilities of €0.00 Mil as of Mar. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Current Deferred Taxes Liabilities too high?
InnoCan Pharma's current Current Deferred Taxes Liabilities is €0.00 Mil. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Current Deferred Taxes Liabilities compare to PG and CL?
InnoCan Pharma's Current Deferred Taxes Liabilities of €0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Consumer Packaged Goods company?
A good Current Deferred Taxes Liabilities depends on the Consumer Packaged Goods industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Current Deferred Taxes Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.51, compared to a current price of €1.51 — trading 84.2% below its estimated fair value. The current Current Deferred Taxes Liabilities is €0.00 Mil. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Current Deferred Taxes Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.51 is trading 84.2% below its estimated GF Value™ of €9.51. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Current Deferred Taxes Liabilities: €0.00 Mil
  • GF Value™: €9.51 vs. price of €1.51 (84.2% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score

Get the complete analysis for FRA:IP40

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€9.51
GF Value